Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV71 vaccine efficacy in children
NCT03582761Phase 4Completed
- Sponsor
- Jiangsu Provincial Center for Disease Control and Prevention
- Start
- May 2019
- Primary completion
- May 2020
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of inactivated EV71 vaccine in HIV-associated central nervous system involvement (HAND), sponsored by Jiangsu Provincial Center for Disease Control and Prevention. Primary endpoint: Odds ratio of the immunization of EV-A71 vaccine at 12 months. Started May 2019; status: completed.
02
Drugs
inactivated EV71 vaccine
03
Conditions
HIV-associated central nervous system involvement (HAND)
Beyond the preview
Go deeper on NCT03582761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03582761.